Ignite Creation Date:
2025-12-24 @ 7:01 PM
Ignite Modification Date:
2025-12-29 @ 6:40 PM
Study NCT ID:
NCT00757757
Status:
TERMINATED
Last Update Posted:
2020-12-19
First Post:
2008-09-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Overview
Official Title:
A Phase I/II Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases
Status:
TERMINATED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: